Representative publications

Litigation support, expert review, and expert option

Abraham I. Trends, changes, and disruptions: the fragile economics of cancer treatments. The Oncologist 2023;28:193-195.

Arku D, et al. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning. Expert Opinion on Drug Safety 2022;21:1235-1238.

Thiede RM, et al. Does synthetic pharmacotherapy still have a place in treating chronic urticaria? Expert Opinion on Pharmacotherapy 2022;23:1563-1567.

Choi B, et al. The decline in e-cigarette use among youth in the United States – an encouraging trend but an ongoing public health challenge. JAMA Network Open 2021;4:e2112464.

Abraham I, et al. Staging systems to predict metastatic cutaneous squamous cell carcinoma: unsatisfactory for clinical use, but some less so? JAMA Dermatology 2018;154:1391-1392.

Gharaibeh M, et al. Economic evaluations of first-line chemotherapy regimens for pancreatic cancer: a critical review. PharmacoEconomics 2017;35:83-95.

Abraham I, et al. Arguing (about) the value of cancer care. Journal of the National Comprehensive Cancer Network 2016;14:1487-1489.

Abraham I. Preparing for the third decade of biosimilars. Expert Opinion on Biological Therapy 2023;23:651-652.

Calamia M, Abraham I. The economics of biosimilars: addressing unmet medical needs in low- and middle-income countries. Expert Opinion on Biological Therapy 2023;23:653-657.

Alkhatib N. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert Opinion on Biological Therapy 2023;23:671-677.

Abraham I, et al. What does it take to provide cancer patients with comprehensive medication therapy management services for oral chemotherapy? Expert Opinion on Drug Safety 2016;15:413-415.

Abraham I, MacDonald K. Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations. Expert Opinion on Drug Safety 2012;11:885-887.

Disclosure: The publications listed are limited to expert reviews and expert opinions. They exclude litigation-related material. They blend articles reporting on studies and projects contracted to MATRIX45 and predecessor companies, independent projects initiated by MATRIX45, as well as academic projects by Ivo Abraham’s academic research groups.